#USA #Boston #Mana.bio #RNA Therapy #Mina™

Mina™: The Dawn of a New Era in RNA Therapy

On September 17, 2025, Mana.bio, a pioneering biotechnology company at the crossroads of artificial intelligence and RNA delivery, announced a groundbreaking innovation in the realm of biomedicine: Mina™, the world’s first large language model (LLM) agent specifically engineered for lipid nanoparticles (LNPs). This revolutionary tool has been referred to as a "ChatGPT for LNPs," and its public accessibility marks a significant milestone in accelerating scientific discovery and the advancement of gene therapy and RNA-based medicines.



Yogev Debi, co-founder and CEO of Mana.bio, pointed out that while artificial intelligence has transformed numerous sectors, its full potential in biology has yet to be realized. He stated, “At Mana, we have already made decisive progress in RNA delivery by leveraging AI, demonstrating that it can lead to entirely new scientific methodologies. With the launch of Mina, we aren't just introducing a tool; we're opening a new chapter in how science is conducted. We envision a future where AI-driven platforms accelerate discovery, bridging the gap between the lab and the patient's bedside, ultimately enhancing human health.”

Mina is designed to be a revolutionary asset for scientists engaged in RNA delivery and therapeutic development. By providing access to reference data, predictive modeling, and optimized formulation strategies, Mina is set to enhance the pace of discovery, dismantle barriers to innovation, and empower researchers to develop new therapies with greater precision and confidence.

Accessible at mina.mana.bio, this platform is available to researchers and scientists around the world. It includes several tailored features intended to facilitate experimentation, data analysis, and LNP design. Key functionalities of Mina include:

1. Predictive Modeling: It allows researchers to predict critical characteristics of LNPs, such as particle size, enabling them to optimize formulations earlier in the development cycle.
2. Organized Data Extraction: This feature provides access to high-quality, standardized data from reliable public scientific sources, ensuring accuracy and dependability in data gathering.
3. Formulation Optimization: Mina provides insights on key performance factors like stability, tropism, and safety, allowing a seamless transition from concept to clinical applications.
4. Public Data Exploration: This functionality aids in uncovering patterns and trends in existing LNP research, fueling innovation.

While Mana.bio retains exclusive access to its most advanced predictive models and proprietary datasets, the company is committed to collaborating with partners eager to harness the full capabilities of the Mina platform.

About Mana.bio

Mana.bio is a biotechnology firm dedicated to developing AI-powered solutions for RNA-based therapies. With the world's largest LNP dataset and proprietary AI models, Mana.bio is speeding up the future of drug development and delivery to improve lives globally.

For media inquiries, please contact: [email protected]